The present invention relates to a capsule formulation comprising together with an NSAID with anti-inflammatory analgesic and antipyretic activities an H2 receptor antagonist used for preventing or minimizing gastrointestinal side effects caused by NSAID.

The present invention is related to a pharmaceutical formulation which comprises NSAID having antiinflamatory analgesic and antipyretic effect together with an H2 receptor antagonist used for preventing and minimizing the gastrointestinal side effects of NSAID. According to another aspect the present invention relates to the fact that the pharmaceutical formulation comprising NSAID as the first drug substance and H2 receptor antagonist as second active substance is a novel solid oral multilayer ...

This invention is related to a novel pharmaceutical composition of entecavir monohydrate comprising sodium starch glycolate and sodium stearyl fumarate with at least one pharmaceutically acceptable excipient for oral administration for their preparation and use thereof.

This invention is related to a novel pharmaceutical composition comprising entecavir monohydrate having a median particle size greater than 50 µm and its preparation and use thereof.

The present invention relates to a bilayer tablet formulation providing a concomitant immediate release and controlled release.

This invention is a novel pharmaceutical composition of ezetimibe or a pharmaceutically acceptable salt thereof comprising one or more pharmaceutically acceptable excipients having high bioavailability with improved solubility and dissolution rate which is stable throughout the shelflife methods for their preparation and methods for treatment using the same.

Una composición farmacéutica de pramipexol o una de sus sales solvatos e hidratos farmacéuticamente aceptables que comprende glicolato de almidón sódico y dihidrato de fosfato de calcio dibásico con al menos un excipiente farmacéuticamente aceptable.

Disolución acuosa libre de EDTA de meloxicam en combinación con meglumina para administración por vía oral o parenteral que comprende uno o más excipientes farmacéuticamente aceptables caracterizada porque la disolución comprende NN-dimetilacetamida y propilenglicol.

This invention is a novel pharmaceutical composition of ezetimibe or a pharmaceutically acceptable salt thereof comprising one or more pharmaceutically acceptable excipients having high bioavailability with improved solubility and dissolution rate which is stable throughout the shelflife methods for their preparation and methods for treatment using the same.